Dec 28, 2023
Join the experts for recent updates on estrogen
receptor-positive (ER+)/HER2-negative (HER2-) metastatic breast
cancer (MBC) progressing on cyclin-dependent kinase (CDK) 4/6
inhibitors.
Learning Objectives & Disclosures:
https://www.medscape.org/viewarticle/999406?ecd=bdc_podcast_libsyn_mscpedu